<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694555/" ref="ordinalpos=991&amp;ncbi_uid=1936001&amp;link_uid=PMC2694555" image-link="/pmc/articles/PMC2694555/figure/F3/" class="imagepopup">Fig. (3).  From: Can Systems Biology Understand <span class="highlight" style="background-color:">Pathway</span> Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of <span class="highlight" style="background-color:">Pathway</span> Activation. </a></div><br /><div class="p4l_captionBody">Response to pathway inhibitors of tumor cells depends on the mechanism of pathway activation. <b>(a)</b> Tumor cells with EGFR mutation are sensitive to EGFR inhibitor gefitinib or erlotinib, whereas those with RAS mutation are resistant to the same drug, because RAF-MEK-ERK signaling is not inhibited by the drugs. <b>(b)</b> When the PI3K pathway is hyperactivated by PI3K mutation or by PTEN loss, tumor cells are sensitive to rapamycin, which inhibits mTOR downstream of the pathway. However, the HER2 inhibitor Herceptin cannot stop the deregulated signal, because it does not inhibit hyperactivation downstream.</div></div>